Refers to pregnenolone derivative compounds of formula (i) wherein R1 is alkyl alkoxy C1 C1 - 8 - 8 NS, NO2, amino, COOH, Oh, COOCH3, N3 or Halogen R2 is H, Oh, alkyl alkoxy C1 - 8 - 8 alquenilo C1, C2, 3 - 6 optionally substituted benzyl or phenyl optionally substituted.Preferred compounds are: 3 - (P - hidroxibenciloxi) - 3 - (P - pregnenolone and pregnenolone metilbenciloxi) - 3 - (P - etilbenciloxi) - pregnenolone among others. It also relates to a preparation method and a Pharmaceutical composition. These compounds are inhibitors of the CB1 receptor being useful in the treatment of steatosis, kidney disease, glaucomaSE REFIERE A COMPUESTOS DERIVADOS DE PREGNENOLONA DE FORMULA (I) DONDE R1 ES ALQUILO C1-8, ALCOXI C1-8, CN, NO2, AMINO, COOH, COOCH3, OH, N3 O HALOGENO R2 ES H, OH, ALQUILO C1-8, ALCOXI C1-8, ALQUENILO C2-6, HALOGENO, BENCILO OPCIONALMENTE SUSTITUIDO O FENILO OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 3-(p-HIDROXIBENCILOXI)-PREGNENOLONA 3-(p-METILBENCILOXI)-PREGNENOLONA 3-(p-ETILBENCILOXI)-PREGNENOLONA ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR CB1 SIENDO UTILES EN EL TRATAMIENTO DE ESTEATOSIS, NEFROPATIAS, GLAUCOMA
